9939.HK

Kintor Pharmaceutical Limited [9939.HK] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

9939.HK Stock Summary

Top 9939.HK Correlated Resources

9939.HK

Top 10 Correlated ETFs

9939.HK

Top 10 Correlated Stocks

9939.HK

In the News

9939.HK Financial details

Company Rating
Neutral
Market Cap
3.59B
Income
-201.55M
Revenue
174.5K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
328
Optionable
No
Shortable
Yes
Earnings
29 Aug 2022
P/E
-2.95
Forward P/E
-
PEG
0.44
P/S
72.57
P/B
1.5
P/C
-
P/FCF
-3.42
Quick Ratio
4.8
Current Ratio
6.94
Debt / Equity
0.47
LT Debt / Equity
0.15
-
-
EPS (TTM)
-0.55
EPS next Y
-
EPS next Q
-
EPS this Y
65.98%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-19.74%
SMA50
-22.14%
SMA100
-36.45%
Inst Own
-
Inst Trans
-
ROA
-41%
ROE
-53%
ROC
-0.45%
Gross Margin
100%
Oper. Margin
-2453%
Profit Margin
-2460%
Payout
-
Shs Outstand
447.5M
Shs Float
270.22M
-
-
-
-
Target Price
-
52W Range
7.45-46.0
52W High
-82.72%
52W Low
+13.57%
RSI
39.08
Rel Volume
0.2
Avg Volume
7.32M
Volume
1.49M
Perf Week
-0.62%
Perf Month
-20.1%
Perf Quarter
-29.89%
Perf Half Y
-28.25%
-
-
-
-
Beta
-0.14423
-
-
Volatility
0.2%, 1.06%
Prev Close
-1.73%
Price
7.95
Change
-1.12%

9939.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0000.11
Net income per share
-0.29-0.63-1.64-2.72
Operating cash flow per share
-0.31-0.62-1.23-3.4
Free cash flow per share
-0.36-0.82-1.23-3.4
Cash per share
0.370.534.493.41
Book value per share
0.6814.875.35
Tangible book value per share
0.190.494.175.35
Share holders equity per share
0.6814.875.35
Interest debt per share
0.20.180.730.52
Market cap
6.92B7.08B2.72B3.11B
Enterprise value
6.85B6.95B1.88B2.34B
P/E ratio
-63.75-30.46-5.35-3.69
Price to sales ratio
9.91K0090.72
POCF ratio
-60.2-31.06-7.14-2.95
PFCF ratio
-51.5-23.44-7.14-2.95
P/B Ratio
27.4819.161.81.88
PTB ratio
27.4819.161.81.88
EV to sales
9.81K0068.21
Enterprise value over EBITDA
-67.02-30.75-3.74-2.8
EV to operating cash flow
-59.61-30.49-4.92-2.22
EV to free cash flow
-50.99-23.01-4.92-2.22
Earnings yield
-0.02-0.03-0.19-0.27
Free cash flow yield
-0.02-0.04-0.14-0.34
Debt to equity
0.680.50.230.25
Debt to assets
0.410.330.190.2
Net debt to EBITDA
0.660.581.680.92
Current ratio
2.011.558.396.94
Interest coverage
-28.35-126.59-118.37-336.65
Income quality
1.060.980.751.25
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
26.53001.31
Research and developement to revenue
133.520022.43
Intangibles to total assets
0.430.340.120
Capex to operating cash flow
0.170.3300
Capex to revenue
-27.82000
Capex to depreciation
-7.95-15.8800
Stock based compensation to revenue
0000
Graham number
2.123.7713.4218.1
ROIC
-0.84-2.791.3-5.15
Return on tangible assets
-0.45-0.64-0.31-0.41
Graham Net
-0.090.033.382.64
Working capital
109.96M78.03M1.25B1.31B
Tangible asset value
69.58M180.95M1.29B1.66B
Net current asset value
46.42M36.9M1.08B1.11B
Invested capital
0.280.170.150.1
Average receivables
0000
Average payables
049.14M54.34M36.69M
Average inventory
000175.68M
Days sales outstanding
0000
Days payables outstanding
9.69K000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0.04000
Inventory turnover
0000
ROE
-0.43-0.63-0.34-0.51
Capex per share
-0.05-0.200

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2020-06-302020-12-312021-06-302021-12-31 2022-06-30
Revenue per share
00000
Net income per share
00000
Operating cash flow per share
00000
Free cash flow per share
00000
Cash per share
00000
Book value per share
00000
Tangible book value per share
00000
Share holders equity per share
00000
Interest debt per share
00000
Market cap
00000
Enterprise value
-1.58B-843.89M-1.09B-770.42M-102.73M
P/E ratio
00000
Price to sales ratio
00000
POCF ratio
00000
PFCF ratio
00000
P/B Ratio
00000
PTB ratio
00000
EV to sales
00000
Enterprise value over EBITDA
00000
EV to operating cash flow
00000
EV to free cash flow
00000
Earnings yield
00000
Free cash flow yield
00000
Debt to equity
0.210.230.110.250.47
Debt to assets
0.170.190.10.20.32
Net debt to EBITDA
00000
Current ratio
7.598.3927.496.943.44
Interest coverage
00000
Income quality
00000
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.080.120.0900.13
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
00000
ROIC
00000
Return on tangible assets
00000
Graham Net
00000
Working capital
1.57B1.25B1.85B1.31B834.39M
Tangible asset value
1.62B1.29B1.95B1.66B951.86M
Net current asset value
1.43B1.08B1.68B1.11B614.01M
Invested capital
0.120.150.060.10.2
Average receivables
00000
Average payables
00000
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
00000
Capex per share
00000

9939.HK Frequently Asked Questions

What is Kintor Pharmaceutical Limited stock symbol ?

Kintor Pharmaceutical Limited is a CN stock and trading under the symbol 9939.HK

What is Kintor Pharmaceutical Limited stock quote today ?

Kintor Pharmaceutical Limited stock price is $7.95 today.

Is Kintor Pharmaceutical Limited stock public?

Yes, Kintor Pharmaceutical Limited is a publicly traded company.

Something similar

Top by Market Cap
EMBASSY.NS
NVD.DE
AMZN
META
DHR-PB
Top Correlated ETFs
XHS
ZUD.TO
WEAT.L
EWAT.MI
BTEC.L
Top Correlated Stocks
POLY.L
XNCR
1360.HK
MWB.DE
RCOI.L
Similar Market Cap
47I.DE
WDP.BR
3557.TW
1596.HK
VK.PA

Company Profile

Healthcare Biotechnology
  • Volume Average 7.32M
  • Market Capitalization 3.59B
  • Employee 328
  • CEO Dr. Youzhi Tong
  • Headquarters Suzhou,CN
  • IPO Date 2020-05-22
  • Website https://www.kintor.com.cn

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.